SCHEMBL482165

SCHEMBL482165

Clc1ccc(-c2ncc[nH]2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 2/20 0.64
MTOR P42345 1/20 0.63
ADK P55263 1/20 0.63
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 4/20 0.56
CYP19A1 P11511 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
PDE3B Q13370 1/20 0.50
PDE3A Q14432 1/20 0.50
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL31679078 0.89 KDM4E (0.65) NISCHMTORADKKDM4EALDH1A1
SCHEMBL722191 0.89 NISCH (0.78) NISCHMTORADKKDM4EALDH1A1
SCHEMBL862114 0.86 NISCH (0.75) NISCHMTORADKKDM4EALDH1A1
SCHEMBL28823231 0.80 NISCH (0.67) NISCHMTORADKKDM4EALDH1A1
SCHEMBL1425562 0.79 NISCH (0.42) NISCHMTORADKKDM4EALDH1A1
SCHEMBL674010 0.78 NISCH (1.00) NISCHMTORADKKDM4EALDH1A1
SCHEMBL2464174 0.78 NISCH (0.64) NISCHMTORADKKDM4EALDH1A1
SCHEMBL771236 0.78 NISCH (0.64) NISCHMTORADKKDM4EALDH1A1
SCHEMBL22782678 0.78 NISCH (0.64) NISCHMTORADKKDM4EALDH1A1
SCHEMBL1288554 0.78 NISCH (0.52) NISCHMTORADKKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3965766-A1 COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA Bayer Aktiengesellschaft (DE) 2022-03-16 EP claimed
CN-110437226-A A kind of new method constructing drug molecule grains of sand pyrrole denier using DMF and ammonium iodide as four step of cyanylation agent UNIV GUILIN TECHNOLOGY 2019-11-12 CN claimed
CN-110372695-A A kind of new method constructing drug molecule grains of sand pyrrole denier using DMF as three step of formylation reagent 桂林理工大学 2019-10-25 CN claimed
CN-102358739-B Synthetic method for imidazole[1,2-a]pyridine and 2-butyl-5-chloro-1H-imidazole-4-carboxaldehyde compounds GUANGZHOU INST BIOMED & HEALTH 2013-02-20 CN claimed
CN-101735217-B Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2012-09-26 CN claimed
EP-1937669-B9 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA NV (BE) 2012-07-18 EP claimed
CN-101863894-B Tanshinone II A derivative and preparation method and application thereof UNIV GUANGDONG PHARM 2012-07-18 CN claimed
CN-102358739-A Synthetic method for imidazole[1,2-a]pyridine and 2-butyl-5-chloro-1H-imidazole-4-carboxaldehyde compounds GUANGZHOU INST BIOMED & HEALTH 2012-02-22 CN claimed
EP-1937669-B1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA NV (BE) 2012-02-01 EP claimed
CN-101863894-A Tanshinone II A derivative and preparation method and application thereof GUANGDONG PHARMACEUTICAL UNIVERSITY 2010-10-20 CN claimed
CN-101735217-A Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug UNIV GUANGDONG PHARM 2010-06-16 CN claimed
EP-2167508-A1 COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2010-03-31 EP claimed
CN-101379065-A Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same CRYSTALGENOMICS INC (KR) 2009-03-04 CN claimed
WO-2009013477-A1 COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-01-29 WO claimed
CN-101296731-A Novel benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2008-10-29 CN claimed
EP-1937669-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP claimed
WO-2007027959-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-08 WO claimed
US-4411700-A AMIDINE DERIVATIVES FUJI PHOTO FILM CO., LTD. (JP) 1983-10-25 US claimed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 US disclosed
US-4110456-A ANTIHYPERTENSIVE MERCK & CO., INC. (US) 1978-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 NISCH 3272/4885MTOR 1294/4885ADK 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.